VMS Group, an asset management firm, led a $190m Series A+ funding round in Chime Biologics, a CDMO company. The round also saw investment from Fidelity International and Panacea Venture. "The successful completion of this financing round will further accelerate the capacity expansion process of Chime Biologics. With the rapid growth of China's biologics market and the surging demand for CDMO service, Chime Biologics will further leverage on its world-class quality system and commercial-scale manufacturing capabilities to continue providing our customers worldwide with first-class CDMO services," James Huang, Chime Biologics Chairman.